Pozen gets another FDA cold shoulder for its cardio drugs

December 17, 2014 2:10 PM

19 0

The FDA again rejected Pozen's ($POZN) pair of treatments designed to help patients deal with cardiovascular disease, citing the same third-party manufacturing issues that tanked the last application. Pozen claims the supplier has since rectified those concerns but that the agency has been less than cooperative in process.

Pozen's drugs combine aspirin and the proton pump inhibitor omeprazole in two ratios, ideally reducing the risk of death for patients who have experienced heart attacks, strokes, chest pain or revascularization procedures. Back in April, the FDA rejected both candidates after noting some deficiencie...

Read more

To category page